Paris – Ahead of the Global Forum for Vaccine Sovereignty and Innovation in Paris on the 20^th June, analysis from The ONE Campaign finds that just 1.1% of Africa’s vaccine supply actually comes from Africa, with Asia providing over half and Europe over one-third of Africa’s vaccine supply. 

The African Union and Africa CDC proposed an ambitious target to manufacture 60% of Africa’s immunization needs on the continent by 2040. Our new analysis tracks progress toward this goal, identifies the challenges and offers a 6-point plan for accelerating vaccine sovereignty in Africa. 

Key figures: 

• 98.9% of Africa’s vaccine supply is produced outside the continent, leaving Africa vulnerable to supply chain disruptions and vaccine inequality. 

• In 2021, African leaders prioritized vaccine sovereignty, setting a target to produce 60% of Africa’s vaccines by 2040 in Africa.  

• To meet that target, at least 1.5 billion doses must be produced annually on the continent by 2040; that’s 73 times more than what is currently produced on the continent.  

“By 2030, Africa will account for over one-third of global vaccine demand. This makes vaccine sovereignty in Africa more than a target – it a critical imperative to ensure healthy lives across the continent.” said Ndidi Okonkwo Nwuneli, President and CEO of The ONE Campaign. “ The African Union’s 2040 target to produce 60% of the needed vaccines in Africa is a huge step in the right direction. However, vaccine sovereignty will not be achieved overnight. We need comprehensive plans and clear commitments from visionary partners.  Working collaboratively, we can build trust across continents, and ensure that every child has the opportunity not only to survive, but thrive.” 

ONE and its partner NGOs ask France to reaffirm its support for Gavi and mobilize the international community to continue reducing inequalities in access to immunization. We also welcome France’s plans to co-organize the launch of the AVMA with the African Union, in parallel of the launch of Gavi’s investment opportunity. This announcement illustrates France’s commitment to promote the health sovereignty of Africa and will have to be followed by ambitious financial commitments.  

  

*** ENDS***  

Press contact : Charlotte Grignard [email protected] +33622410041 

Please contact us if you would be interested in interviewing a spokesperson from The ONE Campaign in Paris 

Notes to Editor  

The Global Forum for Vaccine Sovereignty and Innovation co-hosted in Paris by France and the African Union Chair, Mauritania, will launch Gavi’s 2026–2030 Investment Opportunity to support its next replenishment – which will raise funds for immunization in lower-income countries for Gavi’s sixth strategic period, from 2026 through 2030. 

The Forum will also see the launch of the African Vaccine Manufacturing Accelerator (AVMA), an innovative financial mechanism, designed by Gavi in close collaboration with Africa Centres for Disease Control and Prevention (Africa CDC), to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing. 

AVMA will make a strong contribution to the African Union’s Partnerships for African Vaccine Manufacturing (PAVM) ambition to manufacture at least 60% of the total vaccine doses required on the continent by 2040, as well as the global effort to strengthen African health sovereignty at all times, including for pandemic preparedness and response. 

About The ONE Campaign  

ONE is a global, nonpartisan organization advocating for the investments needed to create economic opportunities and healthier lives in Africa. Our trusted advocacy uses hard-hitting data, grassroots activism, political engagement, and strategic partnerships to influence decision-makers. Learn more at www.one.org.